Bristol Myers Squibb Reveals Promising Results from Trial of Zeposia for Multiple Sclerosis

Posted on by admin

Phase III DAYBREAK study found consistent safety with Zeposia in patients with relapsing forms of multiple sclerosis.

Leave a Reply

Your email address will not be published. Required fields are marked *